Biotech · Private company

ModernaTX, Inc.

Track this companyFree. Adds ModernaTX, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2525 recruiting or active

Pipeline programs26From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline26

mRNA-1018-H5Phase 3 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1403Phase 3 · Acute GastroenteritisClinicalTrials.gov · fetched Nov 12, 2026
IpilimumabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1189Phase 2 · Epstein-Barr Virus InfectionClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1195Phase 2 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1273Phase 2 · SARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1283Phase 2 · SARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1647Phase 2 · Cytomegalovirus InfectionClinicalTrials.gov · fetched Nov 12, 2026
mRNA-2808Phase 2 · Relapsed or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
mRNA-3927Phase 2 · Propionic AcidemiaClinicalTrials.gov · fetched Nov 12, 2026
mRNA-4157Phase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
mRNA-4359Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
NivolumabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Fluarix TrivalentPhase 1 · Seasonal InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1010Phase 1 · Seasonal InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1345Phase 1 · Respiratory Syncytial VirusClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1365Phase 1 · Respiratory Syncytial VirusClinicalTrials.gov · fetched Nov 12, 2026
mRNA-4106Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
mRNA-4157Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
mRNA-4200Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
NimenrixPhase 1 · Respiratory Syncytial VirusClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
SoC TreatmentPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
mRNA-1273 Variant-containing FormulationSARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsPHASE4 · RECRUITING · started Oct 9, 2026ClinicalTrials.gov NCT07863635 · fetched Nov 12, 2026
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenPHASE1 · RECRUITING · started Oct 7, 2026ClinicalTrials.gov NCT07870330 · fetched Nov 12, 2026
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgePHASE2 · RECRUITING · started Sep 4, 2026ClinicalTrials.gov NCT07808697 · fetched Nov 12, 2026
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)PHASE3 · RECRUITING · started May 4, 2026ClinicalTrials.gov NCT07513376 · fetched Nov 12, 2026
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 23, 2026ClinicalTrials.gov NCT07496450 · fetched Nov 12, 2026
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)PHASE2 · RECRUITING · started Dec 12, 2025ClinicalTrials.gov NCT07221474 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)PHASE4 · ACTIVE_NOT_RECRUITING · started Nov 26, 2025ClinicalTrials.gov NCT07266558 · fetched Nov 12, 2026
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaPHASE1_PHASE2 · RECRUITING · started Sep 30, 2025ClinicalTrials.gov NCT07116616 · fetched Nov 12, 2026
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsPHASE2 · RECRUITING · started Apr 16, 2025ClinicalTrials.gov NCT06735248 · fetched Nov 12, 2026
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsPHASE1 · RECRUITING · started Mar 25, 2025ClinicalTrials.gov NCT06880549 · fetched Nov 12, 2026
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)PHASE2 · RECRUITING · started Mar 11, 2025ClinicalTrials.gov NCT06833073 · fetched Nov 12, 2026
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)PHASE3 · RECRUITING · started Oct 21, 2024ClinicalTrials.gov NCT06623422 · fetched Nov 12, 2026
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 24, 2024ClinicalTrials.gov NCT06592794 · fetched Nov 12, 2026
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsPHASE4 · RECRUITING · started Sep 9, 2024ClinicalTrials.gov NCT06585241 · fetched Nov 12, 2026
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 10, 2024ClinicalTrials.gov NCT06307431 · fetched Nov 12, 2026
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 6, 2023ClinicalTrials.gov NCT06077760 · fetched Nov 12, 2026
A Retrospective Study to Characterize Participants With Propionic AcidemiaRECRUITING · started Jun 16, 2023ClinicalTrials.gov NCT05769621 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 5, 2023ClinicalTrials.gov NCT05683457 · fetched Nov 12, 2026
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsPHASE1 · ACTIVE_NOT_RECRUITING · started Feb 15, 2023ClinicalTrials.gov NCT05743881 · fetched Nov 12, 2026
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Sep 1, 2022ClinicalTrials.gov NCT05533697 · fetched Nov 12, 2026
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 28, 2021ClinicalTrials.gov NCT05164094 · fetched Nov 12, 2026
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 StudyPHASE1_PHASE2 · RECRUITING · started Nov 9, 2021ClinicalTrials.gov NCT05130437 · fetched Nov 12, 2026
Open-Label Study of mRNA-3927 in Participants With Propionic AcidemiaPHASE1_PHASE2 · RECRUITING · started Apr 15, 2021ClinicalTrials.gov NCT04159103 · fetched Nov 12, 2026
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 18, 2019ClinicalTrials.gov NCT03897881 · fetched Nov 12, 2026
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 14, 2017ClinicalTrials.gov NCT03313778 · fetched Nov 12, 2026